Dupixent® (dupilumab) Receives U.S. Approval for Treating Chronic Rhinosinusitis with Nasal Polyps in Adolescents

TARRYTOWN, N.Y. and PARIS – In a significant development for adolescents suffering from Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Regeneron Pharmaceuticals NASDAQ:REGN and Sanofi NASDAQ:SNY, have announced the approval of Dupixent® (dupilumab) by the U.S. regulatory authorities. This marks a monumental milestone as Dupixent® becomes the first and only medication for CRSwNP approved for adolescents in the U.S. As of September 13, 2024, the partnership between Regeneron and Sanofi brings new hope to patients and their families seeking effective treatment options for this chronic inflammatory condition.

Understanding Chronic Rhinosinusitis with Nasal Polyps

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a persistent inflammatory condition characterized by the growth of noncancerous polyps in the nasal passages and sinuses, leading to congestion, difficulty in breathing, and a reduced quality of life. Adolescents with this condition often face challenges managing their symptoms, which can impact their daily activities and overall well-being. The approval of Dupixent® offers a clinically proven option to help reduce polyps and alleviate the symptoms associated with CRSwNP.

The Role of Dupixent® in Treatment

Dupilumab, the active agent in Dupixent®, is a biologic therapy that works by blocking the IL-4 and IL-13 pathways, which are known to contribute to type 2 inflammation, a common pathway in a variety of allergic diseases including CRSwNP. With this approval, Dupixent® becomes an essential therapeutic choice for specialists treating adolescents dealing with CRSwNP. The rigorous clinical trials have demonstrated significant symptom reduction and improvement in the quality of life for patients receiving this treatment.

About Regeneron Pharmaceuticals and Sanofi

Based out of Tarrytown, New York, Regeneron Pharmaceuticals is a leading biotechnology company that has consistently demonstrated a commitment to innovation in the pharmaceutical industry. Sanofi, with headquarters in Paris, France, is a global healthcare company deeply engaged in the research, development, manufacturing, and marketing of therapeutic solutions with a broad international reach. The collaboration between Regeneron and Sanofi has resulted in advancements in treatment options for various conditions, underscoring their shared mission to address unmet medical needs.

Regeneron, Sanofi, Dupixent